GB202200753D0 - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- GB202200753D0 GB202200753D0 GBGB2200753.8A GB202200753A GB202200753D0 GB 202200753 D0 GB202200753 D0 GB 202200753D0 GB 202200753 A GB202200753 A GB 202200753A GB 202200753 D0 GB202200753 D0 GB 202200753D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2200753.8A GB202200753D0 (en) | 2022-01-21 | 2022-01-21 | Pharmaceutical compounds |
| PCT/EP2023/051447 WO2023139241A1 (en) | 2022-01-21 | 2023-01-20 | Heterocyclic compounds as ubiquitin specific protease 7 inhibitors |
| US18/729,403 US20250122223A1 (en) | 2022-01-21 | 2023-01-20 | Heterocyclic compounds as ubiquitin specific protease 7 inhibitors |
| CN202380027580.0A CN118946566A (zh) | 2022-01-21 | 2023-01-20 | 作为泛素特异性蛋白酶7抑制剂的杂环化合物 |
| EP23701878.3A EP4466072A1 (en) | 2022-01-21 | 2023-01-20 | Heterocyclic compounds as ubiquitin specific protease 7 inhibitors |
| JP2024543181A JP2025503052A (ja) | 2022-01-21 | 2023-01-20 | ユビキチン特異的プロテアーゼ７阻害剤としてのヘテロ環式化合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2200753.8A GB202200753D0 (en) | 2022-01-21 | 2022-01-21 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202200753D0 true GB202200753D0 (en) | 2022-03-09 |
Family
ID=80507367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2200753.8A Ceased GB202200753D0 (en) | 2022-01-21 | 2022-01-21 | Pharmaceutical compounds |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250122223A1 (https=) |
| EP (1) | EP4466072A1 (https=) |
| JP (1) | JP2025503052A (https=) |
| CN (1) | CN118946566A (https=) |
| GB (1) | GB202200753D0 (https=) |
| WO (1) | WO2023139241A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202001980D0 (en) * | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| US20240150362A1 (en) | 2022-08-25 | 2024-05-09 | Molecure S.A. | Substituted Pyrrolotriazines |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2200753B (en) | 1986-12-23 | 1991-01-23 | Brookes & Gatehouse | Speed measurement device |
| EP1749822B1 (en) | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| US7875613B2 (en) | 2006-10-30 | 2011-01-25 | Hybrigenics Sa | Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| EP2208725A1 (en) | 2009-01-13 | 2010-07-21 | Hybrigenics S.A. | Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
| WO2010114881A1 (en) | 2009-04-01 | 2010-10-07 | Progenra Inc. | Anti-neoplastic compounds, compositions and methods |
| US20110177105A1 (en) | 2010-01-15 | 2011-07-21 | Roman Lopez | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| US9840491B2 (en) | 2015-02-05 | 2017-12-12 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| CN107531683B (zh) | 2015-03-20 | 2022-05-13 | 豪夫迈·罗氏有限公司 | Usp7抑制剂化合物及使用方法 |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
-
2022
- 2022-01-21 GB GBGB2200753.8A patent/GB202200753D0/en not_active Ceased
-
2023
- 2023-01-20 WO PCT/EP2023/051447 patent/WO2023139241A1/en not_active Ceased
- 2023-01-20 US US18/729,403 patent/US20250122223A1/en active Pending
- 2023-01-20 EP EP23701878.3A patent/EP4466072A1/en active Pending
- 2023-01-20 JP JP2024543181A patent/JP2025503052A/ja active Pending
- 2023-01-20 CN CN202380027580.0A patent/CN118946566A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250122223A1 (en) | 2025-04-17 |
| WO2023139241A1 (en) | 2023-07-27 |
| EP4466072A1 (en) | 2024-11-27 |
| JP2025503052A (ja) | 2025-01-30 |
| CN118946566A (zh) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201911928D0 (en) | Pharmaceutical compounds | |
| GB202020191D0 (en) | Pharmaceutical compounds | |
| GB202010409D0 (en) | Pharmaceutical compounds | |
| GB202010408D0 (en) | Pharmaceutical compounds | |
| GB201911944D0 (en) | Pharmaceutical compounds | |
| GB201915273D0 (en) | Pharmaceutical compounds | |
| GB201914910D0 (en) | Pharmaceutical compounds | |
| GB201915932D0 (en) | Pharmaceutical compounds | |
| GB202200753D0 (en) | Pharmaceutical compounds | |
| GB202111193D0 (en) | Pharmaceutical compounds | |
| GB202104097D0 (en) | Pharmaceutical compounds | |
| IL291570A (en) | Pharmaceutical preparations | |
| GB202201283D0 (en) | Pharmaceutical compounds | |
| GB202213819D0 (en) | Pharmaceutical compound | |
| GB202102602D0 (en) | Pharmaceutical compounds | |
| IL326026A (en) | Pharmaceutical materials | |
| GB202312534D0 (en) | Pharmaceutical compounds | |
| GB202311018D0 (en) | Pharmaceutical compounds | |
| GB202206327D0 (en) | Pharmaceutical compounds | |
| GB202117969D0 (en) | Pharmaceutical compounds | |
| GB202217888D0 (en) | Pharmaceutical compound | |
| GB202212967D0 (en) | Pharmaceutical compound | |
| GB202202070D0 (en) | Pharmaceutical compound | |
| GB202007163D0 (en) | Pharmaceutical compounds | |
| GB202003646D0 (en) | Pharmaceutical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |